Browsing by Author Kiely, Belinda Emma

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 16 of 16
Issue DateTitleAuthor(s)Citation
2015Doctor to doctor communication of prognosis in metastatic cancer: a review of letters from medical oncologists to referring doctorsBeale, Philip; Blinman, Prunella; Kiely, Belinda Emma; Della Fiorentina, Stephen; Moth, Erin B; Parry, Jane; Stockler, Martin; Central Clinical School: Medicine; School of Public Health: Public Health; NH&MRC Clinical Trials CentreDoctor to doctor communication of prognosis in metastatic cancer: a review of letters from medical oncologists to referring doctors, Internal Medicine Journal, vol.45, 9, 2015,pp 909-915
2014Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trialsKiely, Belinda Emma; Stockler, Martin; West, Timothy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Medical Sciences: Brain & Mind Research InstituteEstimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials, European Journal of Cancer, vol.50, 11, 2014,pp 1916-1924
2017Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancerKiely, Belinda Emma; Russell, Peter; Bressel, Mathias; Camm, S.; et al, Various; Grant, Peter Thomas; Hickey, Martha; Lee, Y. C.; McLachlan, Sue Anne; Milne, R; Picken, S; Smith, C.; NH&MRC Clinical Trials Centre; Central Clinical School: PathologyImproved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer, Familial Cancer, vol.16, 4, 2017,pp 461-469
2018Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016)Houssami, Nehmat; Kiely, Belinda Emma; Lord, Sarah (Sally); Daniels, Benjamin; Lu, Christine; Pearson, Sallie-Anne; Ward, Robyn L; School of Public Health: Public Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreLong-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016), Breast Cancer Research and Treatment, vol.171, 1, 2018,pp 151-159
2018Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016)Houssami, Nehmat; Kiely, Belinda Emma; Lord, Sarah (Sally); Daniels, Benjamin; Lu, Christine; Pearson, Sallie-Anne; Ward, Robyn L; School of Public Health: Public Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreLong-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016), Breast Cancer Research and Treatment, vol.171, 1, 2018,pp 151-159
2018Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016)Houssami, Nehmat; Kiely, Belinda Emma; Lord, Sarah (Sally); Daniels, Benjamin; Lu, Christine; Pearson, Sallie-Anne; Ward, Robyn L; School of Public Health: Public Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreLong-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016), Breast Cancer Research and Treatment, vol.171, 1, 2018,pp 151-159
2018Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016)Houssami, Nehmat; Kiely, Belinda Emma; Lord, Sarah (Sally); Daniels, Benjamin; Lu, Christine; Pearson, Sallie-Anne; Ward, Robyn L; School of Public Health: Public Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreLong-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016), Breast Cancer Research and Treatment, vol.171, 1, 2018,pp 151-159
2018Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016)Houssami, Nehmat; Kiely, Belinda Emma; Lord, Sarah (Sally); Daniels, Benjamin; Lu, Christine; Pearson, Sallie-Anne; Ward, Robyn L; School of Public Health: Public Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreLong-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016), Breast Cancer Research and Treatment, vol.171, 1, 2018,pp 151-159
2018Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016)Houssami, Nehmat; Kiely, Belinda Emma; Lord, Sarah (Sally); Daniels, Benjamin; Lu, Christine; Pearson, Sallie-Anne; Ward, Robyn L; School of Public Health: Public Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreLong-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016), Breast Cancer Research and Treatment, vol.171, 1, 2018,pp 151-159
2018Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016)Houssami, Nehmat; Kiely, Belinda Emma; Lord, Sarah (Sally); Daniels, Benjamin; Lu, Christine; Pearson, Sallie-Anne; Ward, Robyn L; School of Public Health: Public Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreLong-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016), Breast Cancer Research and Treatment, vol.171, 1, 2018,pp 151-159
2013The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' EstimatesBeale, Philip; Kiely, Belinda Emma; Martin, Andrew; Stockler, Martin; Tattersall, Martin; Wilcken, Nicholas; Abdi, Ehtesham A; Glare, Paul A.; Glasgow, Amanda; Goldstein, David; Jefford, Michael; Nowak, Anna K.; Wyld, David; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead)The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates, Journal of Clinical Oncology, vol.31, 28, 2013,pp 3565-3571
2017More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trialsKiely, Belinda Emma; Stockler, Martin; Vasista, Anuradha; West, Timothy; Wilcken, Nicholas; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Medical Sciences: Brain and Mind Centre; Western Clinical School: Medicine (Westmead)More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials, The Breast, vol.31, N/A, 2017,pp 99-104
2015Small HER2-positive breast cancer: Should size affect adjuvant treatment?Beith, Jane; Kiely, Belinda Emma; Bastick, Patricia; Descallar, Joseph; Lynch, Jodi; Mok, Kelly; Tognela, Annette; Central Clinical School: Medicine; NH&MRC Clinical Trials CentreSmall HER2-positive breast cancer: Should size affect adjuvant treatment?, Clinical Breast Cancer, vol.15, 4, 2015,pp 277-284
2013Survival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trialsKiely, Belinda Emma; Stockler, Martin; Adams, D H; Chantrill, L; Della-Fiorentina, Stephen; Thientosapol, E S; Tran, T T; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreSurvival times of women with metastatic breast cancer starting first-line chemotherapy in routine clinical practice versus contemporary randomised trials, Internal Medicine Journal, vol.43, 8, 2013,pp 883-888
2017Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: Protocol detailing observations in a whole of population cohortHoussami, Nehmat; Kiely, Belinda Emma; Lord, Sarah (Sally); Daniels, B; Haywood, Philip; Lu, C; Pearson, Sallie-Anne; Ward, R; School of Public Health: Public Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreUse and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort, BMJ Open, vol.7, 1, 2017,pp 1-12
2017Use of palliative chemotherapy in patients aged 80 years and over with incurable cancer: experience at three Sydney cancer centresBlinman, Prunella; Kiely, Belinda Emma; Beale, Philip; Bray, Victoria; Della-Fiorentina, Stephen; Ip, Emilia; Pokorny, A M J; School of Public Health: Public Health; NH&MRC Clinical Trials CentreUse of palliative chemotherapy in patients aged 80 years and over with incurable cancer: experience at three Sydney cancer centres, Internal Medicine Journal, vol.47, 1, 2017,pp 75-81